Literature DB >> 8657947

Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).

T Murakami1, R L Baron, M S Peterson, J H Oliver, P L Davis, S R Confer, M P Federle.   

Abstract

PURPOSE: To determine the efficacy of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP) at magnetic resonance (MR) imaging for evaluation of hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: MR imaging at 1.5 T was performed in 20 patients with 65 HCC nodules. T1- and T2-weighted spin-echo and T1-weighted gradient-recalled-echo images were obtained before and after administration of 5 mumol/kg Mn-DPDP. Readers individually evaluated the pre- and postcontrast images for detection of tumor nodules, with subsequent consensus reading for interpretation discrepancies. Quantitative measurements of tumor-liver contrast-to-noise ratio (C/N) were also performed. Enhancement characteristics were correlated with histologic tumor differentiation.
RESULTS: Precontrast images depicted 50 lesions in 17 patients, and postcontrast images depicted 49 lesions in 20 patients. Combination of pre- and postcontrast images enabled detection of 53 lesions in 20 patients. Three lesions (three patients) were seen only on postcontrast images. Four lesions (three patients) were seen only on precontrast images. Reader evaluation of tumor conspicuity showed a significant preference for precontrast T2-weighted SE images (P < .01). Quantitative evaluation showed a significant increase in C/N on postcontrast T1-weighted images (P < .01). Well-differentiated lesions showed significantly greater enhancement than that of poorly differentiated lesions (P < .05).
CONCLUSION: Mn-DPDP-enhanced MR imaging depicts HCC tumors not visualized with unenhanced studies. The degree of tumor enhancement correlates with histologic differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657947     DOI: 10.1148/radiology.200.1.8657947

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

1.  Mn-DPDP-enhanced 24-h delayed-scan MRI of hepatocellular carcinoma is correlated with histology.

Authors:  Deng-Bin Wang; Kang-Rong Zhou; Meng-Su Zeng; Ke-Min Chen; Yi-Xiang J Wang
Journal:  Eur Radiol       Date:  2003-06-12       Impact factor: 5.315

2.  Novel Preparation Methods of (52)Mn for ImmunoPET Imaging.

Authors:  Stephen A Graves; Reinier Hernandez; Jesper Fonslet; Christopher G England; Hector F Valdovinos; Paul A Ellison; Todd E Barnhart; Dennis R Elema; Charles P Theuer; Weibo Cai; Robert J Nickles; Gregory W Severin
Journal:  Bioconjug Chem       Date:  2015-09-10       Impact factor: 4.774

3.  Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

Authors:  C S Peña; S Saini; R L Baron; B A Hamm; G Morana; R Caudana; A Giovagnoni; A Villa; A Carriero; D Mathieu; M W Bourne; M A Kirchin; G Pirovano; A Spinazzi
Journal:  Korean J Radiol       Date:  2001 Oct-Dec       Impact factor: 3.500

Review 4.  Hepatobiliary MR imaging with gadolinium-based contrast agents.

Authors:  Alex Frydrychowicz; Meghan G Lubner; Jeffrey J Brown; Elmar M Merkle; Scott K Nagle; Neil M Rofsky; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-03       Impact factor: 4.813

Review 5.  Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.

Authors:  Ying Zhang; Kazushi Numata; Yuewu Du; Shin Maeda
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

6.  Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.

Authors:  Luis Martí-Bonmatí; Amura F Fog; Bart Op de Beeck; Pauline Kane; Hans Fagertun
Journal:  Eur Radiol       Date:  2002-12-19       Impact factor: 5.315

Review 7.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

Review 8.  Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Authors:  Carlo Bartolozzi; Laura Crocetti; Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Daniela Campani
Journal:  Eur Radiol       Date:  2007-02-16       Impact factor: 7.034

9.  MRI in detection of hepatocellular carcinoma (HCC).

Authors:  Subba R Digumarthy; Dushyant V Sahani; Sanjay Saini
Journal:  Cancer Imaging       Date:  2005-04-13       Impact factor: 3.909

Review 10.  Contrast agents for hepatic MRI.

Authors:  Giovanni Morana; Elisabetta Salviato; Alessandro Guarise
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.